title: Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
authors.forename: K
authors.initials: K
authors.lastname: Hohloch
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: W
authors.initials: W
authors.lastname: Jurczak
authors.forename: A
authors.initials: A
authors.lastname: Deptala
authors.forename: M
authors.initials: M
authors.lastname: Lorsbach
authors.forename: C
authors.initials: C
authors.lastname: Windemuth-Kiesselbach
authors.forename: G G
authors.initials: GG
authors.lastname: Wulf
authors.forename: L H
authors.initials: LH
authors.lastname: Truemper
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003625:Data Collection; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan